CKPT vs. GANX, AADI, EQ, HCWB, EGRX, BLRX, NBRV, LTRN, CLNN, and RPHM
Should you be buying Checkpoint Therapeutics stock or one of its competitors? The main competitors of Checkpoint Therapeutics include Gain Therapeutics (GANX), Aadi Bioscience (AADI), Equillium (EQ), HCW Biologics (HCWB), Eagle Pharmaceuticals (EGRX), BioLineRx (BLRX), Nabriva Therapeutics (NBRV), Lantern Pharma (LTRN), Clene (CLNN), and Reneo Pharmaceuticals (RPHM). These companies are all part of the "pharmaceutical preparations" industry.
Gain Therapeutics (NASDAQ:GANX) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, community ranking, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.
Gain Therapeutics has higher earnings, but lower revenue than Checkpoint Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Checkpoint Therapeutics, indicating that it is currently the more affordable of the two stocks.
Gain Therapeutics has a net margin of 0.00% compared to Gain Therapeutics' net margin of -50,336.89%. Gain Therapeutics' return on equity of 0.00% beat Checkpoint Therapeutics' return on equity.
In the previous week, Checkpoint Therapeutics had 5 more articles in the media than Gain Therapeutics. MarketBeat recorded 6 mentions for Checkpoint Therapeutics and 1 mentions for Gain Therapeutics. Checkpoint Therapeutics' average media sentiment score of 1.35 beat Gain Therapeutics' score of 0.17 indicating that Gain Therapeutics is being referred to more favorably in the media.
Gain Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.
Checkpoint Therapeutics received 148 more outperform votes than Gain Therapeutics when rated by MarketBeat users. Likewise, 66.15% of users gave Checkpoint Therapeutics an outperform vote while only 61.11% of users gave Gain Therapeutics an outperform vote.
Gain Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 187.16%. Checkpoint Therapeutics has a consensus price target of $22.60, indicating a potential upside of 1,330.38%. Given Gain Therapeutics' higher probable upside, analysts plainly believe Checkpoint Therapeutics is more favorable than Gain Therapeutics.
12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 22.0% of Checkpoint Therapeutics shares are held by institutional investors. 11.0% of Gain Therapeutics shares are held by insiders. Comparatively, 2.1% of Checkpoint Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Checkpoint Therapeutics beats Gain Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Checkpoint Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CKPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Checkpoint Therapeutics Competitors List
Related Companies and Tools
